Meta-Analysis of Melatonin Supplementation during Controlled Ovarian Hyperstimulation for Women Undergoing Assisted Reproductive Technology

doi:10.12280/gjszjk.20200396

Abstract

Abstract:

Objective: To evaluate the effectiveness of melatonin supplementation during controlled ovarian hyperstimulation for women undergoing assisted reproductive technology.Methods: We searched PubMed, Embase, the Cochrane Library, the CNKI Database, VIP Database, Wanfang Database and the Chinese Biomedicine (CBM) Database for eligible studies published by the end of January 2020. Two independent evaluators screened the randomized controlled trials retrieved the effects of melatonin supplementation during controlled ovarian hyperstimulation in women undergoing assisted reproductive technology. The quality of the included studies was assessed, and the data were extracted for meta-analysis using RevMan 5.3.Results: A total of 6 RCTs involving 767 cycles were included. Among them, 419 cycles were in the melatonin group and 348 cycles in the control group. The meta-analysis showed that the numbers of MⅡ oocytes, high-quality embryos and the E₂ levels on hCG day in the melatonin group was significantly higher than those in the control group (P<0.05). The melatonin supplementation during controlled ovarian hyperstimulation moderately elevated the clinical pregnancy rate, but the difference was not significant (WMD=1.34, P=0.08, 95%CI: 0.96-1.86). However, there were no significant differences in the number of oocytes retrieved and embryos transplanted, fertilization rate and abortion rate between the two groups (P>0.05).Conclusions: The currently available evidence suggests that melatonin supplementation during controlled ovarian hyperstimulation for women undergoing assisted reproductive technology can improve the numbers of MⅡ oocytes and high-quality embryos, and clinical pregnancy rate. Larger sample size and multicenter RCTs are needed to verify the above conclusions.

Key words: Reproductive techniques, assisted, Melatonin, Ovulation induction, Randomized controlled trial, Meta-analysis

ZHOU Li-yuan, WEN Yi, TANG Jun, KANG Ge-hua, MAO Zeng-hui. Meta-Analysis of Melatonin Supplementation during Controlled Ovarian Hyperstimulation for Women Undergoing Assisted Reproductive Technology[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(1): 11-17.

Figures/Tables 11

References 28

[1]	Gnoth C, Godehardt E, Frank-Herrmann P, et al. Definition and prevalence of subfertility and infertility[J]. Hum Reprod, 2005,20(5):1144-1147. doi: 10.1093/humrep/deh870.
[2]	Zegers-Hochschild F, Adamson GD, de Mouzon J, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009[J]. Fertil Steril, 2009,92(5):1520-1524. doi: 10.1016/j.fertnstert.2009.09.009.
[3]	Bai F, Wang DY, Fan YJ, et al. Assisted reproductive technology service availability, efficacy and safety in mainland China: 2016[J]. Hum Reprod, 2020,35(2):446-452. doi: 10.1093/humrep/dez245.
[4]	Pang Y, Jiang X, Zhao S, et al. Beneficial role of melatonin in protecting mammalian gametes and embryos from oxidative damage[J]. J Int Agricul, 2018,17(10):2320-2335. doi: 10.1016/S2095-3119(18)61942-2.
[5]	Xu Y, Nisenblat V, Lu C, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial[J]. Reprod Biol Endocrinol, 2018,16(1):29. doi: 10.1186/s12958-018-0343-0.
[6]	Liu Y, Hu L, Fan L, et al. Efficacy of dehydroepiandrosterone (DHEA) supplementation for in vitro fertilization and embryo transfer cycles: a systematic review and meta-analysis[J]. Gynecol Endocrinol, 2018,34(3):178-183. doi: 10.1080/09513590.2017.1391202.
[7]	Carlomagno G, Minini M, Tilotta M, et al. From Implantation to Birth: Insight into Molecular Melatonin Functions[J]. Int J Mol Sci, 2018,19(9):2802. doi: 10.3390/ijms19092802.
[8]	Nakamura Y, Tamura H, Takayama H, et al. Increased endogenous level of melatonin in preovulatory human follicles does not directly influence progesterone production[J]. Fertil Steril, 2003,80(4):1012-1016. doi: 10.1016/s0015-0282(03)01008-2.
[9]	Tamura H, Takasaki A, Taketani T, et al. Melatonin and female reproduction[J]. J Obstet Gynaecol Res, 2014,40(1):1-11. doi: 10.1111/jog.12177.
[10]	Tamura H, Tanabe M, Jozaki M, et al. Antioxidative action of melatonin and reproduction[J]. Glycative Stress Res, 2019,6(3):192-197. doi: 10.24659/gsr.6.3_192.
[11]	Lv D, Tan T, Zhu T, et al. Leptin mediates the effects of melatonin on female reproduction in mammals[J]. J Pineal Res, 2019,66(3):e12559. doi: 10.1111/jpi.12559.
[12]	Zou H, Chen B, Ding D, et al. Melatonin promotes the development of immature oocytes from the COH cycle into healthy offspring by protecting mitochondrial function[J]. J Pineal Res, 2020,68(1):e12621. doi: 10.1111/jpi.12621.
[13]	Batıoğlu AS, Sahin U, Gürlek B, et al. The efficacy of melatonin administration on oocyte quality[J]. Gynecol Endocrinol, 2012,28(2):91-93. doi: 10.3109/09513590.2011.589925.
[14]	Eryilmaz OG, Devran A, Sarikaya E, et al. Melatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems[J]. J Assist Reprod Genet, 2011,28(9):815-820. doi: 10.1007/s10815-011-9604-y.
[15]	Fernando S, Wallace EM, Vollenhoven B, et al. Melatonin in Assisted Reproductive Technology: A Pilot Double-Blind Randomized Placebo-Controlled Clinical Trial[J]. Front Endocrinol(Lausanne), 2018,9:545. doi: 10.3389/fendo.2018.00545.
[16]	Jahromi BN, Sadeghi S, Alipour S, et al. Effect of Melatonin on the Outcome of Assisted Reproductive Technique Cycles in Women with Diminished Ovarian Reserve: A Double-Blinded Randomized Clinical Trial[J]. Iran J Med Sci, 2017,42(1):73-78.
[17]	Pacchiarotti A, Carlomagno G, Antonini G, et al. Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome[J]. Gynecol Endocrinol, 2016,32(1):69-73. doi: 10.3109/09513590.2015.1101444.
[18]	Rizzo P, Raffone E, Benedetto V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial[J]. Eur Rev Med Pharmacol Sci, 2010,14(6):555-561.
[19]	El Mouatassim S, Guérin P, Ménézo Y. Expression of genes encoding antioxidant enzymes in human and mouse oocytes during the final stages of maturation[J]. Mol Hum Reprod, 1999,5(8):720-725. doi: 10.1093/molehr/5.8.720.
[20]	Olszak-Wsik K, Anna Bednarska-Czerwińska, Olejek A, et al. From "Every Day" Hormonal to Oxidative Stress Biomarkers in Blood and Follicular Fluid, to Embryo Quality and Pregnancy Success?[J]. Oxid Med Cell Longev, 2019,2019(2):1-11. doi: 10.1155/2019/1092415.
[21]	Tamura H, Takasaki A, Miwa I, et al. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate[J]. J Pineal Res, 2008,44(3):280-287. doi: 10.1111/j.1600-079X.2007.00524.x.
[22]	Zhang X, Li XH, Ma X, et al. Redox-induced apoptosis of human oocytes in resting follicles in vitro[J]. J Soc Gynecol Investig, 2006,13(6):451-458. doi: 10.1016/j.jsgi.2006.05.005.
[23]	Davoodi F, Maryam S, Vaso T, et al. The influence of reactive oxygen species on in vitro fertilization success[J]. Int J Knowledge, 2016,15:1037-1040.
[24]	Barros VRP, Monte APO, Santos JMS, et al. Melatonin improves development, mitochondrial function and promotes the meiotic resumption of sheep oocytes from in vitro grown secondary follicles[J]. Theriogenology, 2020,144:67-73. doi: 10.1016/j.theriogenology.2019.12.006.
[25]	Galano A, Reiter RJ. Melatonin and its metabolites vs oxidative stress: From individual actions to collective protection[J]. J Pineal Res, 2018,65(1):e12514. doi: 10.1111/jpi.12514.
[26]	Tamura H, Takasaki A, Taketani T, et al. The role of melatonin as an antioxidant in the follicle[J]. J Ovarian Res, 2012,5:5. doi: 10.1186/1757-2215-5-5.
[27]	刘婷婷, 章志国. 褪黑素在卵母细胞发育中的作用及体外成熟培养中的应用[J]. 国际生殖健康/计划生育杂志, 2014,33(5):375-378.
[28]	Seko LM, Moroni RM, Leitao VM, et al. Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis of randomized controlled trials[J]. Fertil Steril, 2014,101(1):154-161.e4. doi: 10.1016/j.fertnstert.2013.09.036.

纳入研究	样本量（周期）	年龄（岁）	COH方案	药物使用情况	使用时间	观察指标	ART
Batıolu等^[13] （2012年）	褪黑素组：40个周期对照组：45个周期	褪黑素组：（30.4±5.6）岁对照组：（29.7±4.9）岁	激动剂长方案：月经黄体中期开始使用GnRHa降调节,当达到降调标准后使用FSH 150 U/d启动,当主导卵泡平均直径达18 mm时用hCG扳机,hCG扳机后36 h取卵。	褪黑素组：褪黑素3 mg/d（未说明服用时间及方法）; 对照组：空白对照	IVF助孕期间	①②③⑥⑦	IVF
Eryilmaz等^[14] （2011年）	褪黑素组：30个周期对照组：30个周期	褪黑素组：（30.1±4.0）岁对照组：（29.9±3.6）岁	激动剂长方案：月经第21天开始使用亮丙瑞林0.5 mg/d,使用10~14 d,当达到垂体脱敏后使用FSH 150 U/d启动,当3个及3个以上卵泡直径达18 mm以上时使用hCG扳机,hCG扳机后36 h取卵。	褪黑素组：褪黑素3 mg/d,每晚 22：00~23：00单次服用; 对照组：空白对照	取卵周期月经第3~5天开始至hCG扳机日	①②③⑤⑦	IVF
Fernando等^[15] （2018年）	褪黑素组：120个周期对照组：40个周期	褪黑素组：（35.5±4.1）岁对照组：（35.2±4.2）岁	拮抗剂方案：所有患者均接受固定GnRH_A方案,FSH 150~450 U/d启动,专家决定hCG扳机时机,hCG扳机后36 h取卵。	褪黑素组：褪黑素（2mg,2次/d; 4 mg,2次/d;8 mg,2次/d）; 对照组：安慰剂,2次/d	取卵周期月经第2天开始至取卵日	②④⑤⑥⑦	IVF/ICSI
Jahromi等^[16] （2017年）	褪黑素组：32个周期对照组：34个周期	褪黑素组：（35.0±5.1）岁对照组：（35.1±5.1）岁	激动剂长方案：月经第21天开始使用亮丙瑞林0.2 mg/d,月经第2天使用FSH启动,当2个及2个及以上卵泡直径达17~18 mm以上时使用hCG扳机,hCG扳机后34~36 h取卵。	褪黑素组：褪黑素3 mg/d,睡前服用; 对照组：安慰剂,睡前服用	促性腺激素促排卵周期上一个月经周期的第15天开始至取卵日	①③④⑤⑥⑦	IVF/ICSI
Pacchiarotti等^[17] （2016年）	褪黑素组：165个周期对照组：166个周期	褪黑素组：（31.2±2.1）岁对照组：（31.5±2.8）岁	激动剂长方案：月经第21天开始使用曲普瑞林0.1 mg/d,月经第2天使用FSH 225 U/d启动,50%的卵泡直径达到20mm时使用hCG扳机,hCG扳机后36 h取卵。	褪黑素组：褪黑素3 mg/d +肌醇 4 000 mg/d+叶酸400 mg/d,每晚20：00~21：00服用对照组：肌醇4 000 mg/d+叶酸400 mg/d,每晚20：00~21：00服用	取卵周期月经第1天至胚胎移植后14 d	①②⑤⑦	IVF/ICSI
Rizzo等^[18] （2010年）	褪黑素组：32个周期对照组：33个周期	褪黑素组：（37.81 ± 2.61）岁对照组：（38.09 ± 1.97）岁	激动剂长方案：月经黄体中期开始使用GnRHa降调节,当达到降调标准后使用FSH 150 U/d启动,当主导卵泡直径达18 mm时注射hCG,hCG扳机后36 h取卵。	褪黑素组：褪黑素（3 mg/d,1次/d）+肌醇（2 g,2次/d）+叶酸（200 mg,1次/d）（未规定具体服药间）; 对照组：肌醇（2 g,2次/d）+叶酸（200 mg,1次/d）（未规定具体服药间）	GnRHa降调日开始至hCG日	①②③④⑤⑥⑦	IVF

纳入研究	样本量（周期）	年龄（岁）	COH方案	药物使用情况	使用时间	观察指标	ART
Batıolu等^[13] （2012年）	褪黑素组：40个周期对照组：45个周期	褪黑素组：（30.4±5.6）岁对照组：（29.7±4.9）岁	激动剂长方案：月经黄体中期开始使用GnRHa降调节,当达到降调标准后使用FSH 150 U/d启动,当主导卵泡平均直径达18 mm时用hCG扳机,hCG扳机后36 h取卵。	褪黑素组：褪黑素3 mg/d（未说明服用时间及方法）; 对照组：空白对照	IVF助孕期间	①②③⑥⑦	IVF
Eryilmaz等^[14] （2011年）	褪黑素组：30个周期对照组：30个周期	褪黑素组：（30.1±4.0）岁对照组：（29.9±3.6）岁	激动剂长方案：月经第21天开始使用亮丙瑞林0.5 mg/d,使用10~14 d,当达到垂体脱敏后使用FSH 150 U/d启动,当3个及3个以上卵泡直径达18 mm以上时使用hCG扳机,hCG扳机后36 h取卵。	褪黑素组：褪黑素3 mg/d,每晚 22：00~23：00单次服用; 对照组：空白对照	取卵周期月经第3~5天开始至hCG扳机日	①②③⑤⑦	IVF
Fernando等^[15] （2018年）	褪黑素组：120个周期对照组：40个周期	褪黑素组：（35.5±4.1）岁对照组：（35.2±4.2）岁	拮抗剂方案：所有患者均接受固定GnRH_A方案,FSH 150~450 U/d启动,专家决定hCG扳机时机,hCG扳机后36 h取卵。	褪黑素组：褪黑素（2mg,2次/d; 4 mg,2次/d;8 mg,2次/d）; 对照组：安慰剂,2次/d	取卵周期月经第2天开始至取卵日	②④⑤⑥⑦	IVF/ICSI
Jahromi等^[16] （2017年）	褪黑素组：32个周期对照组：34个周期	褪黑素组：（35.0±5.1）岁对照组：（35.1±5.1）岁	激动剂长方案：月经第21天开始使用亮丙瑞林0.2 mg/d,月经第2天使用FSH启动,当2个及2个及以上卵泡直径达17~18 mm以上时使用hCG扳机,hCG扳机后34~36 h取卵。	褪黑素组：褪黑素3 mg/d,睡前服用; 对照组：安慰剂,睡前服用	促性腺激素促排卵周期上一个月经周期的第15天开始至取卵日	①③④⑤⑥⑦	IVF/ICSI
Pacchiarotti等^[17] （2016年）	褪黑素组：165个周期对照组：166个周期	褪黑素组：（31.2±2.1）岁对照组：（31.5±2.8）岁	激动剂长方案：月经第21天开始使用曲普瑞林0.1 mg/d,月经第2天使用FSH 225 U/d启动,50%的卵泡直径达到20mm时使用hCG扳机,hCG扳机后36 h取卵。	褪黑素组：褪黑素3 mg/d +肌醇 4 000 mg/d+叶酸400 mg/d,每晚20：00~21：00服用对照组：肌醇4 000 mg/d+叶酸400 mg/d,每晚20：00~21：00服用	取卵周期月经第1天至胚胎移植后14 d	①②⑤⑦	IVF/ICSI
Rizzo等^[18] （2010年）	褪黑素组：32个周期对照组：33个周期	褪黑素组：（37.81 ± 2.61）岁对照组：（38.09 ± 1.97）岁	激动剂长方案：月经黄体中期开始使用GnRHa降调节,当达到降调标准后使用FSH 150 U/d启动,当主导卵泡直径达18 mm时注射hCG,hCG扳机后36 h取卵。	褪黑素组：褪黑素（3 mg/d,1次/d）+肌醇（2 g,2次/d）+叶酸（200 mg,1次/d）（未规定具体服药间）; 对照组：肌醇（2 g,2次/d）+叶酸（200 mg,1次/d）（未规定具体服药间）	GnRHa降调日开始至hCG日	①②③④⑤⑥⑦	IVF